LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021/ PRNewswire/-- Today, Boston Scientific Corporation announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System during a late ...

PARIS, Boston Scientific Corporation reports positive results from two trials evaluating new, innovative drug eluting stent (DES) technologies, which are emerging treatment options for coronary heart ...

Boston Scientific announced that its drug-eluting peripheral stent achieved the highest 12-month primary patency rate among other investigational devices to treat blocked arteries in the leg, a ...

SAN DIEGO and MARLBOROUGH, Mass., Sept. 22, 2018 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting ...

Boston Scientific Corporation (NYSE: BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances meeting. Data presented ...

Boston Scientific found guilty of infringing on drug-eluting stent patent, fined $42M By Andrea Park Feb 3, 2023 11:17am Boston Scientific intellectual property lawsuit patent lawsuit ...

NATICK, Mass., Boston Scientific Corporation's ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and ...

Boston Scientific Corp., Natick, Mass., says it is expanding its manufacturing capabilities in Minnesota, one of two locations where the company makes its Taxus drug-eluting stent.

"The availability of the Eluvia Stent System to European patients, paired with the expansion of our existing clinical program, demonstrates the momentum of our drug-eluting portfolio in combatting ...

Marlborough medical device giant Boston Scientific Corp. is standing by one of its drug-eluting vascular stents after the FDA launched a probe into reports that it and similar devices are linked ...

Global drug eluting stents market valued at $4.6 billion in 2010The US drug eluting stents market grew at the CAGR of 8.6% between 2003 and 2010Boston Scientific and Abbott Laboratories are market ...

WASHINGTON (CBS.MW) -- Boston Scientific will release today nine-month results from its Taxus IV paclitaxel-eluting stent clinical trial at the Transcatheter Cardiovascular Therapeutics conference ...